MétaCan
Menu
Back to cohort
Record W4414625586 · doi:10.1016/j.cmi.2025.09.013

Safety and immunogenicity of adjuvanted respiratory syncytial virus vaccine in high-risk transplant recipients: an interventional cohort study

2025· article· en· W4414625586 on OpenAlexafffund
Victoria Hall, Adrian A Alexander, Faranak Mavandadnejad, Madeline Kern-Smith, Rujun Kang, Sapna Humar, Poramed Winichakoon, Rochelle Johnstone, Meghan Aversa, Igor Novitzky‐Basso, Pascal M. Lavoie, Deepali Kumar, Jonas Mattsson, Victor H. Ferreira

Bibliographic record

VenueClinical Microbiology and Infection · 2025
Typearticle
Languageen
FieldMedicine
TopicRespiratory viral infections research
Canadian institutionsToronto General HospitalPrincess Margaret Cancer CentreBC Children's HospitalUniversity Health Network
FundersAmerican Society of TransplantationBC Children’s Hospital FoundationCanadian Institutes of Health ResearchTakeda CanadaNational Health and Medical Research CouncilState Government of VictoriaPhysicians' Services Incorporated Foundation
KeywordsSeroconversionImmunogenicityVaccinationCohort studyVirusRespiratory systemCohort

Abstract

fetched live from OpenAlex

Objectives Allogeneic haematopoietic cell transplant (alloHCT) and lung transplant (LT) recipients are at highest risk for severe respiratory syncytial virus (RSV) disease, even as compared to other immunocompromised groups. Notably, these groups were excluded from published RSV vaccine clinical trials. The aim of this study was to determine the safety and immunogenicity of adjuvanted RSVPreF3 vaccine in adult alloHCT and LT recipients. Methods Adult alloHCT (≥6 months posttransplant) and LT (≥3 months posttransplant) recipients were enrolled and administered a single dose of adjuvanted RSVPreF3 vaccine. Blood samples were collected at baseline and 4−6 weeks postimmunization to assess neutralizing antibodies (NAb), anti-RSVPreF-IgG antibody levels and RSV-specific polyfunctional T-cells. Safety was assessed through participant-led diaries and follow-up. Results Eighty-six participants (46 alloHCT, 40 LT) were enrolled, with median follow-up of 191 days (interquartile range [IQR] 170-248). The median age was 59 years (IQR 45.5−67.3) for LT and 64 years (IQR 59−69) for alloHCT recipients. NAb titres increased postvaccination in both groups (alloHCT: 1.3-fold, LT: 3.0-fold; p < 0.0001). Seroconversion by NAb occurred in 15 of 45 (33.3%) alloHCT and 19 of 39 (48.7%) LT recipients. IgG binding antibody levels increased significantly in both groups (3.3-fold in LT, p=0.0018; 2.3-fold in alloHCT, p=0.0015). CD4 + polyfunctional T-cell responses were detected in 30 of 42 (71.4%) alloHCT and 28/35 (80.0%) LT recipients postvaccination. CD8 + T-cell responses were lower, but frequencies increased in LT recipients after vaccination (p = 0.024). Overall, the vaccine was well tolerated with grade 1 pain the most reported adverse event (54/86, 62.8%). There was no study intervention-related withdrawal. Three LT recipients developed RSV infection postvaccination; two required hospitalization. Conclusions The adjuvanted RSVPreF3 vaccine was immunogenic and well tolerated with modest seroconversion but robust CD4 + T-cell responses. These data support the benefit of RSV vaccination but underscore the need for further strategies to optimize NAb and CD8 + T-cell responses in this high-risk population.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame machine prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.

metaresearch head score (Codex)0.001
metaresearch head score (Gemma)0.001
Version: metacan-v3-hybrid-931329e0061cValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Observational · Consensus signal: Observational
GenreCandidate signal: Empirical · Consensus signal: Empirical
Teacher disagreement score0.001
Threshold uncertainty score0.006

Distilled classifier scores by category (both heads)

CategoryCodexGemma
Metaresearch0.0010.001
Meta-epidemiology (narrow)0.0000.000
Meta-epidemiology (broad)0.0000.001
Bibliometrics0.0000.000
Science and technology studies0.0000.000
Scholarly communication0.0010.000
Open science0.0000.000
Research integrity0.0000.001
Insufficient payload (model declined to judge)0.0010.000

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.034
GPT teacher head0.398
Teacher spread0.365 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designObservational
Domainnot available
GenreEmpirical

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations5
Published2025
Admission routes2
Has abstractyes

Explore more

Same venueClinical Microbiology and InfectionSame topicRespiratory viral infections researchFrench-language works237,207